EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gyrase and Topoisomerase IV as Antibacterial Targets for Gepotidacin and Zoliflodacin: Teaching Old Enzymes New Tricks

Neil Osheroff iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27010496 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Neil Osheroff. Beteiligte Einrichtung: Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. Hauptthemen laut MEDLINE: Acenaphthenes, Anti-Bacterial Agents, Barbiturates, DNA Gyrase. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIAID NIH HHS, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The essential bacterial type II topoisomerases gyrase and topoisomerase IV have been exploited as the therapeutic targets of fluoroquinolone antibacterials for over four decades. Despite their broad utility, the effectiveness of fluoroquinolones has been increasingly undermined by the widespread emergence of target-mediated resistance, highlighting the need for alternative therapeutic strategies. Recent advances have produced two mechanistically distinct classes of gyrase/topoisomerase IV-targeted antibacterials: the triazaacenaphthylenes and the spiropyrimidinetriones. The first-in-class agents gepotidacin and zoliflodacin, respectively, were approved for human use in 2025, representing the first new antibacterial classes targeting these enzymes in decades. This commentary examines the mechanisms of action of these agents, contrasts their interactions with gyrase and topoisomerase IV relative to fluoroquinolones, and considers their potential to address resistance while preserving the long-term clinical viability of therapy directed against the bacterial type II topoisomerases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcenaphthenesAnti-Bacterial AgentsBarbituratesDNA GyraseDNA Topoisomerase IVNaphthyridinesOxazolidinonesHumansFluoroquinolonesTopoisomerase II InhibitorsHeterocyclic Compounds, 3-RingIsoxazolesMorpholinesSpiro Compounds

Stichwörter der Autor:innen

antibacterialfluoroquinolonegepotidacingyrasetopoisomerase IVzoliflodacin

Substanzen

AcenaphthenesAnti-Bacterial AgentsBarbituratesDNA GyraseDNA Topoisomerase IVFluoroquinolonesgepotidacinNaphthyridinesOxazolidinonesTopoisomerase II Inhibitors

Autor:innen und Institutionen

  • Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
  • Department of Medicine (Hematology/Oncology), Vanderbilt University School of Medicine, Nashville, TN 37232, USA.

ORCID-Profile: Neil Osheroff

Förderung

  • NIGMS NIH HHS
  • NIAID NIH HHS
  • National Institute of General Medical Sciences
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Osheroff, N. (2026). Gyrase and Topoisomerase IV as Antibacterial Targets for Gepotidacin and Zoliflodacin: Teaching Old Enzymes New Tricks. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27010496

Vancouver

Osheroff N. Gyrase and Topoisomerase IV as Antibacterial Targets for Gepotidacin and Zoliflodacin: Teaching Old Enzymes New Tricks. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27010496

BibTeX
@article{Osheroff2026,
  author = {Osheroff, Neil},
  title = {Gyrase and Topoisomerase IV as Antibacterial Targets for Gepotidacin and Zoliflodacin: Teaching Old Enzymes New Tricks},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27010496}
}
Kostenlos starten →